Welcome to our dedicated page for Livanova Plc SEC filings (Ticker: LIVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. SEC filings for LivaNova PLC (NASDAQ: LIVN), a global medical technology company headquartered in London and incorporated in England and Wales. As a foreign private issuer with securities listed in the United States, LivaNova files reports with the Securities and Exchange Commission that document material events, financial results, and corporate governance changes.
Among the filings available are Form 8‑K current reports, which LivaNova uses to announce items such as quarterly financial results, business update conference calls, and board appointments. For example, the company has filed 8‑K reports to furnish press releases on results for quarters ended June 30 and September 30, and to disclose the appointment of a new director to its Board and Audit and Compliance Committee.
Investors and analysts can also use this page to locate LivaNova’s annual and periodic reports, which typically include information on its Epilepsy and Cardiopulmonary businesses, neuromodulation therapies such as VNS Therapy, and its global operations in neurological and cardiac conditions. These documents can help readers understand segment performance, risk factors, and other disclosures that complement the company’s press releases.
Stock Titan enhances these filings with AI‑powered summaries that explain the key points of lengthy documents, such as earnings releases or other detailed reports. Real‑time updates from the EDGAR system ensure that new LivaNova filings appear promptly, while AI highlights important sections so users can quickly see what changed, which items are being furnished rather than filed, and how corporate events may relate to LIVN stock.
Users interested in governance and oversight can review filings that describe board composition and committee membership. Those focused on financial performance can concentrate on filings that furnish earnings press releases and related metrics.
LivaNova PLC executive Franco Poletti, President of Cardiopulmonary, exercised 2,140 Stock Appreciation Rights that converted into the same number of ordinary shares at $57.60 per share. To cover the SAR base price and tax liabilities, 2,049 shares were withheld at $62.26 per share, leaving a net increase of 91 shares. Following these routine compensation-related transactions, Poletti holds 8,941 ordinary shares directly and 219 shares indirectly through his spouse. The F-code dispositions reflect share withholding for settlement and taxes, not open-market sales.
LivaNova PLC submitted a notice under Section 219 of the Iran Threat Reduction and Syria Human Rights Act and Section 13(r) that it made the required disclosure in its Annual Report on Form 10-K for the period ended December 31, 2025. The company states the disclosure appears in Part I, Item 1. Business of the Form 10-K.
The notice, dated February 25, 2026, is a formal attestation that the specified Iran/Syria-related disclosure was included in the filed annual report.
LivaNova PLC is a London‑based global medical technology company focused on two segments: Cardiopulmonary and Neuromodulation. It sells heart‑lung machines, oxygenators, perfusion systems, cannulae, and neuromodulation devices such as its VNS Therapy System, serving patients with drug‑resistant epilepsy, difficult‑to‑treat depression, and obstructive sleep apnea.
The company invests in R&D, including AI and software, and runs major clinical programs like the RECOVER depression study and the OSPREY trial for its aura6000 sleep apnea system. For 2025, 53% of net revenue came from the U.S., 19% from Europe, and 28% from the rest of the world. It reports extensive global regulatory, cybersecurity, trade, environmental, and compliance risks and highlights exposure to sanctions regimes through limited sales into Iran and other sanctioned markets.
As of December 31, 2025, LivaNova employed about 3,300 people in 34 countries and emphasizes culture, leadership development, and diversity initiatives as part of its human capital strategy.
LivaNova PLC reported strong fourth-quarter and full-year 2025 results while absorbing a large environmental charge and issuing 2026 guidance. Q4 revenue was $360.9 million, up 12.1% on a reported basis and 9.5% in constant currency, with double‑digit growth in both Cardiopulmonary and Neuromodulation.
For 2025, revenue reached $1.39 billion, rising 10.7% reported and 10.7% organically. GAAP diluted loss per share was $4.45 due largely to a $365.6 million SNIA environmental liability, while adjusted diluted earnings per share increased to $3.90 from $3.38.
The company guided 2026 constant-currency revenue growth between 6.0% and 7.0%, adjusted diluted earnings per share of $4.15 to $4.25, and adjusted free cash flow of $160 million to $180 million. LivaNova also gained significantly higher Medicare reimbursement for VNS Therapy DRE procedures and received U.S. FDA approval for its cloud-based digital health platform, supporting future Neuromodulation growth.
LivaNova PLC institutional holder PRIMECAP Management Co filed Amendment No. 8 to a Schedule 13G reporting its ownership stake. PRIMECAP reports beneficial ownership of 4,224,852 LivaNova shares, representing 7.74% of the class as of 12/31/2025.
The firm has sole voting power over 4,203,362 shares and sole dispositive power over 4,224,852 shares, with no shared voting or dispositive power. PRIMECAP certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of LivaNova.
LivaNova PLC’s ownership report shows several Millennium-affiliated entities holding more than five percent of its ordinary shares as of December 31, 2025. Integrated Core Strategies (US) LLC reports beneficial ownership of 3,065,717 shares, representing 5.6% of the class.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 3,484,082 shares, or 6.4% of the outstanding ordinary shares, through entities over which they have voting control and investment discretion. They certify the holdings are not for the purpose of changing or influencing control of LivaNova.
LivaNova PLC reported a leadership change in its legal function. On January 12, 2026, Senior Vice President, Chief Legal Officer, and Company Secretary Michael Hutchinson notified the company that he is resigning to pursue another opportunity. His last day with LivaNova will be January 26, 2026, creating a near-term transition period for the company’s legal and governance roles.
The company plans to retain an external search firm to begin the process of finding a new Chief Legal Officer, indicating that the board and management aim to bring in a successor through a structured, formal search.
LivaNova PLC officer reports RSU vesting and share withholding for taxes. The President, Cardiopulmonary of LivaNova PLC reported the vesting and settlement of 967 restricted stock units into ordinary shares on 12/15/2025 at an exercise price of $0. On the same date, 416 ordinary shares were disposed of through share withholding at a price of $63.06 to satisfy tax liabilities related to the vesting.
After these transactions, the officer beneficially owns 8,850 ordinary shares directly and 219 ordinary shares indirectly through a spouse. The RSUs were originally granted on December 15, 2023 under the Amended and Restated LivaNova PLC 2022 Incentive Award Plan and vested over a two-year schedule ending December 15, 2025.
LivaNova PLC director reported share activity related to vested restricted stock units. On December 15, 2025, 2,355 ordinary shares were acquired at $0 upon the exercise of previously granted RSUs under the LivaNova PLC 2015 Incentive Award Plan. On the same date, 269 shares were disposed of at $63.06 to cover tax liabilities, leaving 2,086 ordinary shares beneficially owned directly after these transactions.
The RSUs were originally granted on December 15, 2024 with a one-year vesting schedule and were subject to forfeiture before vesting under the plan and award agreement.
LivaNova PLC senior vice president, chief legal officer and company secretary reported routine equity activity related to restricted stock units. On December 15, 2025, 2,254 RSUs vested and were settled in ordinary shares at an exercise price of $0, increasing her directly held stake. On the same date, 1,122 ordinary shares were withheld at $63.06 per share to cover tax obligations, leaving 6,798 ordinary shares held directly after the transactions. The underlying RSUs were originally granted on December 15, 2022, under the LivaNova PLC 2022 Incentive Award Plan with a four-year vesting schedule, and 2,253 RSUs remain beneficially owned following this vesting event.